From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 16 Oct 2019
Summit Therapeutics to Present at the 2019 BIO Investor Forum
News / 11 Oct 2019
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019
News / 07 Oct 2019
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
2019 AGM
The AGM will be held on 19 June 2019 and more information is available from the dedicated page in the investors section
R&D Day
7 October 2019, 8:00am EDT
Our Discuva Platform
Our technology platform is at the heart of our research to develop new mechanism antibiotics